## Estimating Influenza Deaths in Canada, 1992–2009

PLoS ONE 8, e80481 DOI: 10.1371/journal.pone.0080481

Citation Report

#	Article	IF	CITATIONS
1	Are influenza-associated morbidity and mortality estimates for those ≥65 in statistical databases accurate, and an appropriate test of influenza vaccine effectiveness?. Vaccine, 2014, 32, 6884-6901.	3.8	14
2	Leading Indicators and the Evaluation of the Performance of Alerts for Influenza Epidemics. PLoS ONE, 2015, 10, e0141776.	2.5	6
3	Guidance for Practitioners on the Use of Antiviral Drugs to Control Influenza Outbreaks in Long-Term Care Facilities in Canada, 2014-2015 Season. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, e1-e4.	1.9	7
4	Estimating the hospitalization burden associated with influenza and respiratory syncytial virus in <scp>N</scp> ew <scp>Y</scp> ork <scp>C</scp> ity, 2003–2011. Influenza and Other Respiratory Viruses, 2015, 9, 225-233.	3.4	46
5	Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: A cluster randomized trial. Vaccine, 2015, 33, 535-541.	3.8	13
7	A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014–2015 Season. Clinical Infectious Diseases, 2016, 63, 21-32.	5.8	167
8	Protecting our patients by protecting ourselves. Canadian Pharmacists Journal, 2016, 149, 246-255.	0.8	5
9	Active Surveillance for Influenza Reduces but Does Not Eliminate Hospital Exposure to Patients With Influenza. Infection Control and Hospital Epidemiology, 2017, 38, 387-392.	1.8	6
10	Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine, 2017, 35, 2775-2780.	3.8	128
11	Modelled seasonal influenza mortality shows marked differences in risk by age, sex, ethnicity and socioeconomic position in New Zealand. Journal of Infection, 2017, 75, 225-233.	3.3	14
12	Systematic review of the cost-effectiveness of influenza immunization programs. Vaccine, 2017, 35, 1828-1843.	3.8	73
13	Influenza Vaccination for Secondary Prevention of Cardiovascular Events: A Systematic Review. Canadian Journal of Hospital Pharmacy, 2017, 70, 27-34.	0.1	15
14	Containing influenza outbreaks with antiviral use in longâ€ŧerm care facilities in Taiwan, 2008â€⊋014. Influenza and Other Respiratory Viruses, 2018, 12, 287-292.	3.4	11
15	Burden of influenza, respiratory syncytial virus, and other respiratory viruses and the completeness of respiratory viral identification among respiratory inpatients, Canada, 2003â€2014. Influenza and Other Respiratory Viruses, 2018, 12, 113-121.	3.4	43
16	Years of Life Lost Due to Influenza-Attributable Mortality in Older Adults in the Netherlands: A Competing-Risks Approach. American Journal of Epidemiology, 2018, 187, 1791-1798.	3.4	10
17	Influenzaâ€associated mortality in South Africa, 2009â€2013: The importance of choices related to influenza infection proxies. Influenza and Other Respiratory Viruses, 2018, 12, 54-64.	3.4	6
18	Determinants of non-vaccination against seasonal influenza in Canadian adults: findings from the 2015–2016 Influenza Immunization Coverage Survey. Canadian Journal of Public Health, 2018, 109, 369-378.	2.3	17
19	Heterogeneity in Estimates of the Impact of Influenza on Population Mortality: A Systematic Review. American Journal of Epidemiology, 2018, 187, 378-388.	3.4	54

CITATION REPORT

#	Article	IF	CITATIONS
20	Selection Bias in the Assessment of Frailty and Its Role in Influenza Vaccine Effectiveness Evaluation Among Elderly Adults. Journal of Infectious Diseases, 2018, 217, 168-168.	4.0	1
21	Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet, The, 2018, 391, 1285-1300.	13.7	1,870
22	The hospitalization burden of influenza: just the tip of the iceberg?. Global & Regional Health Technology Assessment, 2018, 2018, 228424031877714.	0.1	6
23	Seasonal influenza immunisation: Strategies for older adults. International Journal of Clinical Practice, 2018, 72, e13249.	1.7	27
24	In- and Out-of-hospital Mortality Associated with Seasonal and Pandemic Influenza and Respiratory Syncytial Virus in South Africa, 2009–2013. Clinical Infectious Diseases, 2018, 66, 95-103.	5.8	59
25	Ecological Fallacy, Nonspecific Outcomes, and the Attribution of Disproportionate Vaccine Benefits. Clinical Infectious Diseases, 2018, 66, 1817-1818.	5.8	0
26	Determinants of influenza vaccination among a large adult population in Quebec. Human Vaccines and Immunotherapeutics, 2018, 14, 1-6.	3.3	1
27	Estimating age-specific influenza-associated asthma morbidity in Ontario, Canada. Respiratory Medicine, 2019, 155, 104-112.	2.9	7
28	Methods for detecting seasonal influenza epidemics using a school absenteeism surveillance system. BMC Public Health, 2019, 19, 1232.	2.9	10
29	Determinants of Seasonal Influenza Vaccine Uptake Among the Elderly in the United States: A Systematic Review and Meta-Analysis. Gerontology and Geriatric Medicine, 2019, 5, 233372141987034.	1.5	31
30	Stateâ€level estimates of excess hospitalizations and deaths associated with influenza. Influenza and Other Respiratory Viruses, 2020, 14, 111-121.	3.4	12
31	Influenza-associated disease burden in mainland China: a systematic review and meta-analysis. Scientific Reports, 2021, 11, 2886.	3.3	20
32	Helping Québec Pharmacists Seize the Vaccination Service Opportunity: The Pharmacy Best Practice Workshops. Pharmacy (Basel, Switzerland), 2021, 9, 51.	1.6	2
33	COVID-19's Impact on Willingness to Be Vaccinated against Influenza and COVID-19 during the 2020/2021 Season: Results from an Online Survey of Canadian Adults 50 Years and Older. Vaccines, 2021, 9, 346.	4.4	10
34	Projected impact of a plant-derived vaccine on the burden of seasonal influenza in Canada. Human Vaccines and Immunotherapeutics, 2021, 17, 3643-3651.	3.3	1
35	The Ontario Pharmacy Evidence Network Atlas of Community Pharmacy Influenza Immunizations. Canadian Pharmacists Journal, 2021, 154, 305-311.	0.8	2
36	Simulating influenza epidemics with waning vaccine immunity. Medicine (United States), 2021, 100, e27169.	1.0	2
37	Time-continuous and time-discrete SIR models revisited: theory and applications. Advances in Difference Equations, 2020, 2020, 556.	3.5	17

#	Article	IF	CITATIONS
38	Using a Negative Binomial Regression Model for Early Warning at the Start of a Hand Foot Mouth Disease Epidemic in Dalian, Liaoning Province, China. PLoS ONE, 2016, 11, e0157815.	2.5	6
39	The Annual Burden of Seasonal Influenza in the US Veterans Affairs Population. PLoS ONE, 2017, 12, e0169344.	2.5	32
40	Self-rated health and reasons for non-vaccination against seasonal influenza in Canadian adults with asthma. PLoS ONE, 2017, 12, e0172117.	2.5	13
41	Modelling community-control strategies to protect hospital resources during an influenza pandemic in Ottawa, Canada. PLoS ONE, 2017, 12, e0179315.	2.5	13
42	Point-of-care diagnostic tests for influenza in the emergency department: A cost-effectiveness analysis in a high-risk population from a Canadian perspective. PLoS ONE, 2020, 15, e0242255.	2.5	2
43	Summary of the National Advisory Committee on Immunization (NACI) Statement on Seasonal Influenza Vaccine for 2016–2017. Canada Communicable Disease Report, 2016, 42, 188-192.	1.3	4
44	Summary of the NACI Statement on Seasonal Influenza Vaccine for 2017–2018. Canada Communicable Disease Report, 2017, 43, 96-103.	1.3	8
45	Summary of the NACI Seasonal Influenza Vaccine Statement for 2018–2019. Canada Communicable Disease Report, 2018, 44, 123-128.	1.3	4
46	Summary of the NACI literature review on the comparative effectiveness of subunit and split virus inactivated influenza vaccines in older adults. Canada Communicable Disease Report, 2018, 44, 129-133.	1.3	1
47	Influenza outbreaks in Ontario hospitals, 2012–2016. Canada Communicable Disease Report, 2018, 44, 201-205.	1.3	4
48	Summary of the NACI Seasonal Influenza Vaccine Statement for 2019–2020. Canada Communicable Disease Report, 2019, 45, 149-155.	1.3	18
49	Should individuals use influenza vaccine effectiveness studies to inform their decision to get vaccinated?. Canada Communicable Disease Report, 2019, 45, 156-158.	1.3	3
50	Summary of the NACI Seasonal Influenza Vaccine Statement for 2020–2021. Canada Communicable Disease Report, 2020, 46, 132-137.	1.3	17
51	Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017. Eurosurveillance, 2017, 22, .	7.0	56
52	Influenza in Canada, 2012-2013 season. Canada Communicable Disease Report, 2014, 40, 346-354.	1.3	1
53	Comparison of influenza surveillance data from the Republic of Korea, selected northern hemisphere countries and Hong Kong SAR (China) from 2012 to 2017. Western Pacific Surveillance and Response Journal: WPSAR, 2020, 11, 1-9.	0.6	0
54	National FluWatch mid-season report, 2021–2022: Sporadic influenza activity returns. Canada Communicable Disease Report, 2022, 48, 39-45.	1.3	7
55	Predictors of Influenza Vaccination in Early Rheumatoid Arthritis 2017â€2021: Results From the Canadian Early Arthritis Cohort. ACR Open Rheumatology, 2022, 4, 566-573.	2.1	2

CITATION REPORT

#	Article	IF	CITATIONS
56	Trends in Excess Winter Mortality (EWM) from 1900/01 to 2019/20—Evidence for a Complex System of Multiple Long-Term Trends. International Journal of Environmental Research and Public Health, 2022, 19, 3407.	2.6	11
57	Modelling the Economic Impact of Influenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada. Vaccines, 2022, 10, 1257.	4.4	3
58	Antigenic drift and epidemiological severity of seasonal influenza in Canada. Scientific Reports, 2022, 12, .	3.3	0
59	Estimated mortality due to seasonal influenza in southeast of Iran, 2006/2007 to 2011/2012 influenza seasons. Influenza and Other Respiratory Viruses, 2023, 17, .	3.4	0
60	Parental Attitudes and Perceptions of Support after Brief Clinician Intervention Predict Intentions to Accept the Adjuvanted Seasonal Influenza Vaccination: Findings from the Pediatric Influenza Vaccination Optimization Trial (PIVOT)–I. Vaccines, 2022, 10, 1957.	4.4	1
61	Healthy adults supplemented with a nutraceutical formulation containing Aloe vera gel, rosemary and Poria cocos enhances the effect of influenza vaccination in a randomized, triple-blind, placebo-controlled trial. Frontiers in Nutrition, 0, 10, .	3.7	1
62	Sex differences in adverse events following seasonal influenza vaccines: a meta-analysis of randomised controlled trials. Journal of Epidemiology and Community Health, 2023, 77, 791-801.	3.7	2
63	Impact of the universal seasonal influenza vaccination policy in the province of Manitoba, Canada: A population-based, province-wide record-linkage study. Vaccine, 2023, 41, 6679-6689.	3.8	1